Julia Elvin, MD, PhD, vice president and senior associate medical director, Foundation Medicine, discusses a study of comprehensive genomic profiling with loss of heterozygosity to identify therapeutically relevant subsets of ovarian cancer.
Tisotumab Vedotin Continues to Show Survival Benefits in Recurrent Cervical Cancer
July 22nd 2024An analysis from the innovaTV 301 showed that tisotumab vedotin in the second- and third-line bettered overall survival vs investigator’s choice of chemotherapy in patients with cervical cancer.
Read More